Sarah Cannon Research Institute

Chattanooga, Tennessee 37404

1 studies enrolling now · 4 studies all time

What they study most

Breast Cancer, Carcinoma, Transitional Cell, HER2 Positive Breast Cancer, MSS, PD-L1 Negative, RAS-mutant Colorectal Cancer, Renal Pelvis Neoplasms, Triple Negative Breast Cancer, Ureteral Neoplasms, Urethral Neoplasms, Urinary Bladder Neoplasms, Urologic Neoplasms

Studies at this site

• Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC — Recruiting now
• A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer — Stopped early
• A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer — Completed
• Study of Binimetinib + Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS Mutation — Completed